Inside Bayer Oncology: An Interview With Robert LaCaze

Bayer AG may more often make headlines for its deal-making in consumer health and agriculture, but the massive German conglomerate sees oncology drugs as a key engine of future success within its high-growth pharmaceuticals business. A Q&A with Robert LaCaze, EVP of Bayer's new Oncology Strategic Business Unit.

LaCaze_Robert
Robert LaCaze

Robert LaCaze joined Bayer AG in October 2015 from Bristol-Myers Squibb Co., where he was head of product and portfolio strategy, to help lay the foundation of Bayer’s oncology strategic business unit that went into effect in February 2017. LaCaze was tapped as the unit’s first leader, combining Bayer’s strategic oncology operations, regulatory affairs, clinical development, marketing, medical affairs, pricing and access functions in a single organization to accelerate development and commercialization of new cancer therapies.

Bayer is not a top-10 oncology company, and LaCaze avoids too specifically pinning down the firm’s aspirations in biopharma’s biggest...

More from Business Strategy

More from In Vivo